Close Menu

NEW YORK (GenomeWeb) – Loxo Oncology announced today that it has formed a collaboration with Roche subsidiary Ventana Medical Systems to develop and commercialize a test to identify patients likely to respond to the cancer drug larotrectinib.

Loxo's larotrectinib — also known as LOXO-101 — is an oral inhibitor of tropomyosin receptor kinases (TRK), a family of proteins associated with cellular signaling and tumor growth. The drug is currently under phase I and II testing as a treatment for tumors with TRK fusions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Aug
22
Sponsored by
BC Platforms

This webinar will discuss how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.

Sep
18
Sponsored by
Bionano Genomics

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Oct
03
Sponsored by
Agilent

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.